KIDNEY CANCER UK
(KCUK)

COMMENTS ON THE NICE APPRAISAL CONSULTATION DOCUMET (ACD) FOR THE DRUG AXITINIB IN TREATING ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR SYSTEMIC TREATMENT (ID518)

Dr J P Hanlon
Trustee
KCUK

March, 2014

The Recommendations

KCUK most warmly welcomes the recommendations reached by the Appraisal Committee. If adopted as final recommendations, these will ensure that patients suffering from this deadly disease will have access to second-line treatment with all the benefits that flow from it. KCUK thoroughly approves of the condition that the recommendation is only to apply if the manufacturer provides the drug with the discount agreed in the patient access scheme. It is also pleased to see that the Committee couches its decision in terms of the broader 'a first-line kinase inhibitor' rather than specifying just sinitinib. This removes the possibility of some patients whose first-line treatment indicates the taking of pazopanib being unfairly discriminated against.

Our Gratitude

We would like to express our heart-felt thanks to the Appraisal Committee for arriving at this determination. It's going to mean a lot to patients suffering from advanced renal cell carcinoma

* * * * *